| |
|
|
|
|
|
|
|||
|
Blood, 15 June 2005, Vol. 105, No. 12, pp. 4553-4560. Prepublished online as a Blood First Edition Paper on February 22, 2005; DOI 10.1182/blood-2004-12-4750.
REVIEW IN TRANSLATIONAL HEMATOLOGY From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potentialFrom the Department I of Internal Medicine and The Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; The Burnham Institute, John Reed Laboratory, La Jolla, CA; and the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Reclassification of Hodgkin disease as Hodgkin lymphoma (HL) represents a milestone in the lymphoma field, awarding recent insights in the molecular biology of Hodgkin and Reed-Sternberg (H-RS) cells and their environment. This review summarizes antiapoptotic and proproliferative pathways involved in the pathogenesis of this disease with the ultimate goal of translating laboratory knowledge into clinical decision making. The focus is on potential targets and novel drugs, which are discussed in the context of the complex biology of HL. Considering that HL patients are more likely to die from acute and late treatment-related toxicities than from HL itself, the introduction of targeted, biologically based therapies for HL patients with palliative and eventually curative intention might be justified. (Blood. 2005;105:4553-4560)
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||